Yaseen Arabi1, Ahmad M Deeb2, Hanan Aqeel2, Hanan Balkhy3. 1. Department of Intensive Care, King Saud Bin Abdulaziz University, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia. 2. King Abdullah International Medical Research Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia. 3. Infection Control Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
After more than 3 years of the first reported case of the Middle East respiratory syndrome coronavirus (MERS),[1] we sought to examine the number of PubMed-cited articles on MERS from Saudi Arabia (the most affected country)[2] and other countries. We conducted a PubMed search on November 15, 2015 using the following search keywords: MERS, MERS-CoV, Human Coronavirus-Erasmus Medical Center (HCoV-EMC), Erasmus Medical Center/2012 (EMC), HCoV-EMC/2012, novel coronavirus, and human coronavirus. We classified the articles according to the affiliation of the authors: Articles from Saudi Arabia if all authors are from Saudi Arabia, collaborative articles if the authors are from different countries and at least one author from Saudi Arabia, or articles from non-Saudi Arabia. In addition, we classified the articles into the following categories: Diagnosis, epidemiology, virology/pathogenesis, treatment, prevention, review/commentary/editorial/experiences, animal models, transmission, and social (including health care providers and public). We identified a total of 634 articles on MERS [Table 1]. Of those, 70 (11%) were from Saudi Arabia, 56 (8.8%) were collaborative articles, and 508 (80.1%) from non-Saudi Arabia. The most common article categories in descending order were reviews/commentary/editorial/experiences 215 (33.9%) followed by epidemiology 119 (18.8%), MERS transmission 80 (12.6%), and virology 78 (12.3%). To date, there is no definite therapy or vaccine for MERS-CoV infection. Multiple studies were conducted to discover potential treatment, 55 (8.7%) or prevention/vaccine, 29 (4.6%) for MERS-CoV. However, there is no randomized controlled trial so far. The number of social studies, describing the knowledge, perceptions, or attitudes toward MERS or provide educational activities is very limited. These numbers contrast with what has happened with the severe acute respiratory syndrome (SARS), wherein 33 months of the onset of the outbreak, there were 2854 PubMed publications, 33 of which were clinical trials.[3] This literature search highlights the urgent need for further research on MERS, which requires high level of collaboration.
Table 1
Number and categories of PubMed-cited articles on Middle East respiratory syndrome
Number and categories of PubMed-cited articles on Middle East respiratory syndrome
Authors: Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: Yaseen M Arabi; Adel Alothman; Hanan H Balkhy; Abdulaziz Al-Dawood; Sameera AlJohani; Shmeylan Al Harbi; Suleiman Kojan; Majed Al Jeraisy; Ahmad M Deeb; Abdullah M Assiri; Fahad Al-Hameed; Asim AlSaedi; Yasser Mandourah; Ghaleb A Almekhlafi; Nisreen Murad Sherbeeni; Fatehi Elnour Elzein; Javed Memon; Yusri Taha; Abdullah Almotairi; Khalid A Maghrabi; Ismael Qushmaq; Ali Al Bshabshe; Ayman Kharaba; Sarah Shalhoub; Jesna Jose; Robert A Fowler; Frederick G Hayden; Mohamed A Hussein Journal: Trials Date: 2018-01-30 Impact factor: 2.279